Published in Antimicrob Agents Chemother on June 01, 2006
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother (2008) 2.70
Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol (2008) 2.16
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother (2008) 2.11
A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog (2008) 2.09
In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol (2008) 1.94
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother (2007) 1.85
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother (2013) 1.63
In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol (2009) 1.60
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother (2007) 1.55
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother (2008) 1.40
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother (2012) 1.39
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob Agents Chemother (2008) 1.35
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother (2009) 1.34
Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother (2007) 1.31
Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol (2007) 1.30
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol (2007) 1.26
[Keratomycosis: diagnosis and therapy]. Ophthalmologe (2009) 1.17
Bioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis. Appl Environ Microbiol (2008) 1.16
Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2014) 1.13
Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother (2013) 1.08
Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. J Clin Microbiol (2011) 1.05
Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program. J Clin Microbiol (2011) 1.00
Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J Microbiol (2011) 1.00
Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother (2012) 0.98
In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother (2006) 0.98
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. Antimicrob Agents Chemother (2010) 0.97
Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) (2011) 0.97
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother (2014) 0.96
A five-year survey of dematiaceous fungi in a tropical hospital reveals potential opportunistic species. PLoS One (2014) 0.96
Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol (2010) 0.94
Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole. J Clin Microbiol (2008) 0.93
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica (2013) 0.93
Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients. Infect Drug Resist (2012) 0.93
Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrob Agents Chemother (2012) 0.91
Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. Antimicrob Agents Chemother (2012) 0.90
The Ssk1p response regulator and Chk1p histidine kinase mutants of Candida albicans are hypersensitive to fluconazole and voriconazole. Antimicrob Agents Chemother (2007) 0.89
Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis. J Infect Dis (2013) 0.89
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother (2009) 0.88
Will resistance in fungi emerge on a scale similar to that seen in bacteria? Eur J Clin Microbiol Infect Dis (2008) 0.88
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. Antimicrob Agents Chemother (2008) 0.88
In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds. Antimicrob Agents Chemother (2011) 0.88
Identification of Curvularia lunata by polymerase chain reaction in a case of fungal endophthalmitis. Med Mycol Case Rep (2013) 0.87
Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections. Can J Infect Dis Med Microbiol (2008) 0.85
Role of posaconazole in the management of oropharyngeal and esophageal candidiasis. Ther Clin Risk Manag (2007) 0.85
Yeast colonization and drug susceptibility pattern in the pediatric patients with neutropenia. Jundishapur J Microbiol (2014) 0.85
In vitro susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method. ScientificWorldJournal (2013) 0.85
Treatment with intrastromal and intracameral voriconazole in 2 eyes with Lasiodiplodia theobromae keratitis: case reports. Medicine (Baltimore) (2015) 0.85
In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother (2007) 0.84
Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. Drug Des Devel Ther (2010) 0.82
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. Antimicrob Agents Chemother (2008) 0.81
Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae. Antimicrob Agents Chemother (2006) 0.80
In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey. Jundishapur J Microbiol (2015) 0.79
Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients. Antimicrob Agents Chemother (2013) 0.79
Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole. Infect Drug Resist (2015) 0.78
Posaconazole in the management of refractory invasive fungal infections. Ther Clin Risk Manag (2008) 0.78
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs (2014) 0.77
Posaconazole concentrations in human tissues after allogeneic stem cell transplantation. Antimicrob Agents Chemother (2014) 0.77
Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cell. BMC Microbiol (2008) 0.77
Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story. Haematologica (2014) 0.76
Genetic Analysis Using an Isogenic Mating Pair of Aspergillus fumigatus Identifies Azole Resistance Genes and Lack of MAT Locus's Role in Virulence. PLoS Pathog (2015) 0.76
Targeted Disruption of Melanin Biosynthesis Genes in the Human Pathogenic Fungus Lomentospora prolificans and Its Consequences for Pathogen Survival. Int J Mol Sci (2016) 0.76
Antifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles. Int J Nanomedicine (2015) 0.76
[Infections of the central nervous system in the immuno-compromised]. Nervenarzt (2008) 0.75
Dimorphic fungal osteoarticular infections. Eur J Clin Microbiol Infect Dis (2014) 0.75
Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings. Curr Clin Microbiol Rep (2016) 0.75
Activity of fluconazole and its Cu(II) complex towards Candida species. Med Chem Res (2014) 0.75
Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review. J Clin Pharm Ther (2016) 0.75
Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs. J Vet Intern Med (2015) 0.75
Blad-Containing Oligomer Fungicidal Activity on Human Pathogenic Yeasts. From the Outside to the Inside of the Target Cell. Front Microbiol (2016) 0.75
Candidiasis in Pediatrics; Identification and In vitro Antifungal Susceptibility of the Clinical Isolates. Iran J Ped Hematol Oncol (2016) 0.75
Clinical evaluation of the Sensititre YeastOne plate for testing susceptibility of filamentous fungi to posaconazole. J Clin Microbiol (2007) 0.75
Posaconazole Pharmacokinetics in Healthy Cats after Oral and Intravenous Administration. J Vet Intern Med (2016) 0.75
Role of posaconazole in the treatment of oropharyngeal candidiasis. Infect Drug Resist (2010) 0.75
Posaconazole: An Update of Its Clinical Use. Pharmacy (Basel) (2015) 0.75
Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol (2017) 0.75
Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs. J Vet Intern Med (2017) 0.75
Antifungal therapy in children: an update. Eur J Pediatr (2012) 0.75
Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis (1993) 8.63
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis (2002) 4.56
The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis (1998) 4.33
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother (2002) 3.74
Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis (2001) 3.68
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother (1996) 3.20
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother (1998) 3.06
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother (1997) 2.99
In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother (2002) 2.89
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother (2001) 2.84
In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother (2003) 2.80
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 2.65
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother (1997) 2.63
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother (2002) 2.36
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother (2000) 2.33
Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother (2004) 2.20
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol (1999) 2.10
In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother (2001) 2.03
Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother (2004) 1.98
A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother (2000) 1.98
Posaconazole. Drugs (2005) 1.81
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother (2000) 1.68
Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs (2004) 1.67
Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother (2003) 1.47
History of the development of azole derivatives. Clin Microbiol Infect (2004) 1.45
In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother (2002) 1.42
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother (1997) 1.39
Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds. Antimicrob Agents Chemother (2004) 1.24
Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. J Antimicrob Chemother (2005) 0.97
Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant (2004) 0.94
Invasive mycoses: management and unmet medical needs. Curr Opin Infect Dis (2001) 0.92
Nonfilamentous C. albicans mutants are avirulent. Cell (1997) 13.83
The DNA sequence and comparative analysis of human chromosome 20. Nature (2002) 7.40
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
The DNA sequence and analysis of human chromosome 6. Nature (2003) 4.75
The Source and Prevention of Septic Infection of Wounds. Can Med Assoc J (1941) 4.41
Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet (2001) 4.12
Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother (2001) 3.87
Access to genitourinary medicine clinics in the United Kingdom. Sex Transm Infect (2001) 3.79
The Mechanism of Cross Infection of Wounds in Hospital by Haemolytic Streptococci. Can Med Assoc J (1941) 3.54
Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob Agents Chemother (1996) 3.44
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother (2001) 3.33
Epoxidation of short-chain alkenes by resting-cell suspensions of propane-grown bacteria. Appl Environ Microbiol (1983) 3.30
Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect (2004) 3.25
Source and Transmission of Nasopharyngeal Infections. Br Med J (1946) 3.00
Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J (2002) 2.96
Should men with asymptomatic non-specific urethritis be identified and treated? Int J STD AIDS (2008) 2.66
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 2.65
The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther (2007) 2.59
New light on the history of penicillin. Med Hist (1982) 2.44
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother (2000) 2.33
Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess (2007) 2.23
Delayed side effects of droperidol after ambulatory general anesthesia. Anesth Analg (1989) 2.23
The decision-making value of magnetic resonance cholangiopancreatography in patients seen in a referral center for suspected biliary and pancreatic disease. Am J Gastroenterol (2001) 2.21
Detection of herpes simplex virus DNA in genital and dermal specimens by LightCycler PCR after extraction using the IsoQuick, MagNA Pure, and BioRobot 9604 methods. J Clin Microbiol (2001) 2.16
MEASUREMENT OF GLOMERULAR FILTRATION RATE IN PREMATURE INFANTS. J Clin Invest (1948) 2.13
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol (2001) 2.11
Isolation and restriction endonuclease analysis of mycobacterial DNA. J Gen Microbiol (1986) 2.11
THE SEROLOGICAL DIFFERENTIATION OF PATHOGENIC AND NON-PATHOGENIC STRAINS OF HEMOLYTIC STREPTOCOCCI FROM PARTURIENT WOMEN. J Exp Med (1935) 2.09
Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother (1999) 2.06
Percutaneous endoscopic gastrostomy/jejunostomy (PEG/PEJ) tube placement: a novel approach. Gastrointest Endosc (1997) 2.05
A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother (2000) 1.98
The use of alternative therapies by Auckland general practitioners. N Z Med J (1990) 1.89
Microbial oxidation of gaseous hydrocarbons: epoxidation of C2 to C4 n-alkenes by methylotrophic bacteria. Appl Environ Microbiol (1979) 1.89
Undergraduate teaching of genitourinary medicine in Britain--what are the issues? Genitourin Med (1996) 1.88
Calcium and cell cycle control. Development (1990) 1.87
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother (2000) 1.87
Self-assembly of collagen fibers. Influence of fibrillar alignment and decorin on mechanical properties. Biophys J (1997) 1.77
New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev (2000) 1.75
Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infect Immun (2001) 1.75
Critical roles of a cyclic AMP responsive element and an E-box in regulation of mouse renin gene expression. J Biol Chem (2001) 1.72
Culture with BACTEC Peds Plus/F bottle compared with conventional methods for detection of bacteria in synovial fluid. J Clin Microbiol (2001) 1.68
Urinary retention in a bitch. Vet Rec (1993) 1.68
Microbial oxidation of gaseous hydrocarbons: production of methyl ketones from their corresponding secondary alcohols by methane- and methanol-grown microbes. Appl Environ Microbiol (1979) 1.67
Imaging of the complications of peripherally inserted central venous catheters. Clin Radiol (2009) 1.67
Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother (1998) 1.65
Predicting the onset of net carbon uptake by deciduous forests with soil temperature and climate data: a synthesis of FLUXNET data. Int J Biometeorol (2005) 1.64
Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (2000) 1.64
Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol (1992) 1.64
Fractures of the acetabulum in patients aged 60 years and older: an epidemiological and radiological study. J Bone Joint Surg Br (2010) 1.63
Tinted spectacles and visually sensitive migraine. Cephalalgia (2002) 1.62
Early maternal and neonatal morbidity associated with operative delivery in second stage of labour: a cohort study. Lancet (2001) 1.61
In-hospital mortality rates from acute myocardial infarction by race in U.S. hospitals: findings from the National Hospital Discharge Survey. Circulation (1987) 1.60
A quantitative immunohistochemical study of macroglial cell development in the rat optic nerve: in vivo evidence for two distinct astrocyte lineages. Dev Biol (1985) 1.59
Spatial and temporal emergence of high proliferative potential hematopoietic precursors during murine embryogenesis. Proc Natl Acad Sci U S A (2001) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother (1998) 1.55
2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol (2014) 1.54
Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem (1998) 1.51
Translational control of InsP3-induced chromatin condensation during the early cell cycles of sea urchin embryos. Nature (1988) 1.50
HSV-1 genital infection rare in men over the age of 35 years. Int J STD AIDS (2009) 1.44
Inhibition of dimethyl ether and methane oxidation in Methylococcus capsulatus and Methylosinus trichosporium. J Bacteriol (1976) 1.41
Chlamydia trachomatis detection and non-invasive sampling methods. Lancet (1991) 1.40
Direct detection of 8-oxodeoxyguanosine and 8-oxoguanine by avidin and its analogues. Anal Biochem (1998) 1.40
Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. Clin Chem (1996) 1.40
Impressions in implant dentistry. Br Dent J (2011) 1.39
Unreliable extended-spectrum beta-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates. J Clin Microbiol (2008) 1.39
Patient-initiated delay at a genitourinary medicine clinic: are there public health consequences? Sex Transm Infect (2008) 1.38
Serotyping for homotransplantation. XIX. Experience with an interhospital scheme of cadaver-kidney sharing and tissue typing. JAMA (1969) 1.38
Ayurvedic drugs--are they really safe? J Assoc Physicians India (1990) 1.38
Characterization and transcriptional regulation of the 2'-N-acetyltransferase gene from Providencia stuartii. J Bacteriol (1993) 1.36
Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2007) 1.34
Mutations in ribosomal protein L16 conferring reduced susceptibility to evernimicin (SCH27899): implications for mechanism of action. Antimicrob Agents Chemother (2000) 1.32
The prevalence of eye disease in Leicester: a comparison of adults of Asian and European descent. J R Soc Med (1994) 1.32
NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. Oncogene (2011) 1.32
Serotyping for homotransplantation. XVI. Analysis of kidney transplants from unrelated donors. N Engl J Med (1968) 1.31
Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (1984) 1.31
Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother (1989) 1.30
Megacystis-microcolon-intestinal hypoperistalsis syndrome: a rare cause of intestinal obstruction in the newborn. Br J Radiol (1980) 1.30
An Abd-B class HOX.PBX recognition sequence is required for expression from the mouse Ren-1c gene. J Biol Chem (2001) 1.29
Identification of stroke in the community: a comparison of three methods. Br J Gen Pract (2003) 1.29
Antibiotic G418, a new micrommomospora-produced aminglycoside with activity apainst protozoa and helminths: antiparasitic activity. Antimicrob Agents Chemother (1975) 1.29
Some experiences with the use of arteriovenous fistulae in chronic haemodialysis. Br Med J (1968) 1.29
Changes in motor end-plates resulting from muscle fibre necrosis and regeneration. A light and electron microscopic study of the effects of the depolarizing fraction (cardiotoxin) of Dendroaspis jamesoni venom. J Neurol Sci (1974) 1.28
The Bacteriology of Recently Inflicted Wounds with Special Reference to the Haemolytic Streptococci and Staphylococci. Can Med Assoc J (1942) 1.28
A brain imaging (single photon emission computerized tomography) study of semantic and affective processing in psychopaths. Biol Psychiatry (1997) 1.27
Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women's Heart and Health prospective cohort study. Heart (2006) 1.27
Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother (1998) 1.27
The prevalence of age related cataract in the Asian community in Leicester: a community based study. Eye (Lond) (1990) 1.26
Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother (2000) 1.25
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Evernimicin binds exclusively to the 50S ribosomal subunit and inhibits translation in cell-free systems derived from both gram-positive and gram-negative bacteria. Antimicrob Agents Chemother (2000) 1.23
Oxidant regulation of gene expression and neural tube development: Insights gained from diabetic pregnancy on molecular causes of neural tube defects. Diabetologia (2003) 1.23
Role of proximal promoter elements in regulation of renin gene transcription. J Biol Chem (1996) 1.22
Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ (2002) 1.22
Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res (2000) 1.21
Ciprofloxacin inhibition of experimental fracture healing. J Bone Joint Surg Am (2000) 1.21